Clinical Trial

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-16; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Recruiting 2023-11-26
Trial Details
NCT Number NCT06142656
Lead Sponsor October 6 University
Conditions Poly Cystic Ovary Syndrome
Enrollment 60 participants
Start Date 2023-11-25
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-30